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Introduction
Musculoskeletal conditions represent the most 
common cause of chronic disability worldwide, 
and are associated with a major burden to the 
healthcare system1. They include, but are not 
limited to, osteoarthritis, inflammatory arthritis, 
and musculoskeletal injuries, including sports 
injuries, gout and metabolic bone disease1. Esti-
mates of the global burden of these musculoskel-
etal conditions show a 25% increase over the past 
decade1.
Symptomatic treatments for musculoskeletal 
disease are mainly aimed at reducing pain as-
sociated with these conditions and restore full 
functionality of the affected tissues. To this end, 
nonpharmacological treatments (e.g., massage, 
heat, ice, physiotherapy) may be useful in the 
short term. Pharmacological treatment is based 
on analgesic and/or anti-inflammatory agents 
such as paracetamol or non-steroidal anti-in-
flammatory drugs (NSAIDs); if no response 
occurs, then combination treatment or opioid 
derivatives may be useful. However, pharmaco-
logical therapy, especially when administered 
via a systemic route, can be associated with a 
number of adverse effects, including gastroin-
testinal disturbance, hemorrhage, constipation 
and disorientation1,2. 
Without neglecting the important contribution 
represented by synthetic anti-inflammatory drugs, 
botanical extracts are also used extensively for 
the management of musculoskeletal conditions in 
the effort to limit the risk of adverse events while 
retaining clinical efficacy1,3. Noteworthy, these 
supplementations may be have a beneficial effect 
also on the course of the disease3,4.
Abstract. – Standard pharmacological treat-
ment of musculoskeletal conditions is often 
associated with relevant side effects. Botani-
cal preparations endowed with a good tolera-
bility profile, therefore, could have a role in the 
management of these disorders. Among differ-
ent natural products, Boswellia serrata extracts 
have long been used for the treatment of mus-
culoskeletal disorders, given their marked an-
ti-inflammatory activity and their ability to pro-
mote tissue regeneration. However, standard 
preparations of Boswellia serrata show overall 
modest pharmacokinetic properties, a limitation 
which may ultimately lead to reduced efficacy.
In an effort to improve the pharmacokinet-
ic properties, Casperome®, a lecithin-based for-
mulation of Boswellia serrata extract represent-
ing the whole natural bouquet, has been devel-
oped. This formulation was effective in the treat-
ment of Achilles tendonitis, epicondylitis, radic-
ulopathies, ankle sprains and sport injuries as 
shown in several clinical studies, the majority of 
which with a randomized design and all evaluat-
ing a number of well-recognized parameters of 
efficacy for the therapy of musculoskeletal dis-
order. All studies were consistent in showing a 
prompt decrease of pain and improvement of 
functionality of the affected area after supple-
mentation with Casperome®, without any rele-
vant adverse effect. Remarkably, these symp-
tomatic improvements were paralleled by re-
duced plasmatic levels of inflammatory markers 
and by a diminished need for rescue analgesics.
On these bases, Casperome® may have a role 
in the treatment of musculoskeletal disorders. 
Clinical studies in other similar conditions (e.g., 
osteoarthritis) appear warranted to further in-
vestigate the efficacy of this botanical product 
in more specific settings.
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In particular, Boswellia serrata gum resin 
extract (BSE) containing boswellic acids (BAs) 
as the main bioactive principles, has been shown 
effective in the management of musculoskeletal 
pain and inflammation4-7. A lecithin-based deliv-
ery system of BAs (Casperome®, Indena S.p.A., 
Italy) has been recently developed to enhance 
the pharmacokinetic properties of these com-
pounds8.
We discuss here available evidences on the 
use of BAs in musculoskeletal conditions, fo-
cusing on the recent clinical studies on Cas-
perome®.
Boswellic Acids in Musculoskeletal 
Conditions: an Overview
Boswellic acids are the main bioactive constit-
uents of frankincense, a traditional remedy used 
in Indian, Chinese, and African folk medicine en-
dowed with anti-arthritic, astringent, stimulant, 
expectorant and antiseptic properties9. The most 
important frankincense sources are Boswellia ser-
rata in Northwestern India and Boswellia carterii 
in Africa. 
Several experimental and clinical data show 
the potential of BSE for the treatment of a various 
inflammatory diseases such as bowel diseases 
and asthma5,10-16. Moreover, a number of studies 
do support the rationale for the use of BSE in 
musculoskeletal disorders, thanks to the inhi-
bition of the molecular mechanisms underlying 
these conditions3.
Experimental Studies
Boswellia preparation reduced the synthesis 
and the activation of several inflammation me-
diators (MMP-9 and MMP-13, cycloxygenase-2, 
nitric oxide, prostaglandin E2), thus slowing 
down collagen and cartilage dissolution17-19. De-
creased inflammation, slowed cartilage dete-
rioration and increased synthesis of structural 
proteins were also reported in other in vitro 
studies on a poly-herbal formulation which in-
cluded BSE4,19.
These effects were observed also in animal 
models. In rats, BSE suppressed pro-inflamma-
tory mediators and improved the antioxidant sta-
tus, as reflected by lactoperoxidase, myeloper-
oxidase, catalase, superoxide dismutase (SOD), 
glutathione (GSH), nitric oxide (NO) levels20. 
Together with Withania somnifera, Zingiber of-
ficinale and Curcuma longa, BSE relieved in-
flammation and arthritis, and also reduced the 
synthesis of TNF-α and NO21.
Clinical Studies
According to a Cochrane systematic review, 
BSE presents some benefits in the treatment of 
osteoarthritis, coupled with a low burden of side 
effects, in four clinical, placebo-controlled stud-
ies6. In particular, BSE was superior vs. placebo 
in reducing pain and increasing functionality. 
Indeed, in two well-conducted, double-blind, 
randomized, placebo-controlled studies in pa-
tients with knee osteoarthritis, BSE induced pain 
relief and increased functionality as early as a 
few days since treatment initiation17,22. In a reg-
istry study, the supplementation with Boswellia 
preparation showed benefits in the treatment of 
knee osteoarthritis when added to the standard 
management, ameliorating both symptoms and 
functional status23. It also accelerated functional 
recovery and decreased pain and inflammation in 
hand arthritis induced by work-related overstrain-
ing24. A combination of Curcuma longa and BSE 
was superior over celecoxib – in terms of efficacy 
and safety – in patients with knee osteoarthritis25. 
However, these findings were challenged by the 
non-positive results of another double-blind study 
in rheumatoid arthritis patients26.
Casperome® in the Treatment of 
Musculoskeletal Conditions: Rationale 
and Clinical Evidence
Pharmacokinetic studies in both animal mod-
els and humans have shown that, after oral ad-
ministration of BSE (with a dosage as high as 
3000 mg/day), plasma concentrations of BAs re-
main modest, potentially below the pharmacolog-
ically active concentrations5,8,27. This limitation in 
pharmacokinetic profile has somehow limited the 
use of BSE in clinical practice and its pharmaceu-
tical development. 
Of note, the modest oral adsorption of BAs 
is not surprising. Indeed, these compounds are 
poorly soluble in water, suggesting a tendency to 
self-aggregation. This hypothesis is supported by 
the increased absorption when BSE are adminis-
tered together with food, and therefore self-aggre-
gates may be dissolved biliary salts28. 
These observations provided a rationale for the 
development of a lecithin-based formulation of 
BAs (Casperome®). This formulation improved 
absorption of BAs and enhanced tissue accu-
mulation as showed in an animal study, which 
demonstrated plasma concentrations of BAs well-
above the lower threshold of anti-inflammatory 
activity29. In a subsequent randomized cross-
over study, 12 healthy volunteers alternatively 
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received Casperome® or non-formulated BSE8. 
Overall, a significantly higher (both in terms 
of weight-to-weight and molar comparison) and 
quicker absorption of BAs was observed with the 
administration of Casperome®. 
On these bases, Casperome® has been used in 
several clinical studies of different inflamma-
tory-based conditions, including musculoskel-
etal disorders such as tendinopathies, radicu-
lopathies, ankle sprains and sport-related inju-
ries2,11,14,16,30-33. Clinical evidence on the efficacy 
and safety of Casperome® in these conditions is 
described below.
Tendinopathies 
Achilles tendonitis and epicondylitis are tend-
inopathies commonly encountered in daily prac-
tice. In a randomized trial, with an open design, 
60 patients (30 with Achilles tendonitis and 30 
with epicondylitis) were assigned to physical 
therapy only (n=15 among subjects with Achilles 
tendonitis and n=15 among those with epicondy-
litis) or physical therapy plus Casperome® 250 mg 
based supplement b.i.d (Tendhyal®; n=15 in each 
subgroup)30. Overall, 30 days since the initiation 
of the study, assessment by visual-analogical 
scale showed a lower pain score with Casperome® 
plus physical therapy, as compared with physical 
therapy only both in subjects with Achilles ten-
donitis (1.60±0.34 vs. 3.40±0.45; p<0.05) and in 
those with epicondylitis (1.33±0.39 vs. 2.80±0.40; 
p<0.05) Noteworthy, improved pain reduction 
with Casperome® was already evident at day 7 in 
subjects with epicondylitis. Patients assigned to 
Casperome® group also presented improved func-
tion at 15 and 30 days, compared with those on 
physical therapy only. The proportion of subjects 
needing paracetamol was constantly lower with 
Casperome®.
Radiculopathies
In a prospective, randomized, open-label study 
on patients with cervical and lumbar radiculopathy 
due to nerve root compression, Casperome® 250 
mg in combination with (R+) thioctic acid (Destior 
Bridge®) was compared with (R+) thioctic acid 
only, a neuroprotective and antioxidant agent used 
for the treatment of these conditions31. In more de-
tails, 90 patients were randomly assigned to three 
treatment groups: group DB15+30 received R(+) 
thioctic acid plus Casperome®-based supplement 
for 15 days followed by R(+) thioctic acid only for 
30 days; group DB10+20 received R(+) thioctic 
acid plus Casperome®-based supplement for 10 
days followed by R(+) thioctic acid only for 20 
days; group D received R(+) thioctic acid only for 
30 days. 
Overall, group DB15+30, with a longer expo-
sure to Casperome®, achieved better results than 
group DB10+20 and D in terms of pain control 
and reduction of functional impairment at 10 and 
30 days since treatment initiation. 
During another randomized clinical study, 
Casperome® plus (R+) thioctic acid (the former 
for 10 days, followed by 20 days of thioctic acid 
only) were compared with (R+) thioctic acid only 
in patients with cervical or lumbar radiculopathy 
of moderate severity and neuropathic pain (n=30 
for each group)32. Enrolling criteria included mod-
erate severity, recent onset and neuropathic pain. 
Overall, both treatments determined a signifi-
cant improvement in pain severity and functional 
status at 30 days; however, the improvement vs. 
baseline was already evident at day 10 in subjects 
assigned to Casperome® group.
Ankle Sprains
Ankle sprains represent a reliable model of 
soft tissue injury. In a recent study, patients with 
grade II ankle sprains were advised to either 
follow a standard management (n=37) or to fol-
low standard management plus Casperome® 250 
mg/day (n=35)2. Casperome® supplementation 
significantly reduced both spontaneous and on 
movement pain already at day 3, as compared 
with baseline (spontaneous pain, evaluated by 
VAS: 73.3±5.4 at baseline and 42.2±3.0 at day 
3, p<0.05; on movement pain, 87.4±5.2 and 
31.2±2, respectively, p<0.05). This improvement 
was still evident at day 7. On the other hand, 
patients on standard management only did not 
show any improvement in pain. Noteworthy, 
78% of patients on Casperome® had a complete 
resolution of injury at day 7, vs. 38% of those on 
standard management only. Casperome® added 
to standard management was also more bene-
ficial on other clinical signs and symptoms of 
inflammation than standard management on-
ly. Furthermore, Casperome® supplementation 
allowed measurable plasma level of boswellic 
acids even with a once-daily administration. No 
side effects associated with Casperome® were 
reported.
Sport Injury
In a clinical research on elite young rugby 
players (mean age, 18 years) with acute knee 
pain and inf lammation due to sport trauma, 
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Casperome® 250 mg/day plus standard man-
agement (n=25) was compared with standard 
management only (n=27) in relieving mus-
culoskeletal pain and inf lammation33. After 
a 4-week follow-up, only 6 subjects on Cas-
perome® plus standard management showed 
local pain, vs. 25 at baseline (-20.4%, p<0.05). 
Corresponding figures for rugby players with 
joint effusion and those with hematomas were 
–35.3% and -28.2%, respectively (p<0.05 for 
all comparisons). Subjects in the Casperome® 
group also showed increased pain-free walk-
ing distance at the treadmill test (baseline: 
34.8±8.2 meters; 4 weeks: 188±12.7; p<0.05) 
[Figure 1], and had lower concentrations of 
biomarkers of inf lammation such as CRP and 
of cartilage degradation such as COMP. On 
the other hand, no improvement vs. baseline 
was observed for standard management on-
ly in any parameter. Noteworthy, players on 
Casperome® showed a more evident decrease 
in high temperature areas of the injured limb 
compared with those on standard management 
only (-66% vs. -44%; p<0.05). The maximum 
temperature area associated with injury de-
creased in only 4 days of supplementation 
with Casperome® supporting a faster relief 
with this botanical preparation. Moreover, in 
the Casperome® group the reduction in the 
need for other analgesic treatments was sig-
nificantly greater than in the standard-man-
agement group: at 4 weeks, only 2 out of 25 
subjects on Casperome® needed NSAIDs vs. 
9/27 in the control group (p<0.05; Figure 2). 
No side effects were reported.
Discussion
Musculoskeletal disorders are frequently en-
countered in clinical practice and are associated 
with important disability and major healthcare 
burden. Of note, standard pharmacological treat-
ment of these conditions is often associated with 
relevant side effects, which may limit their use.
Botanical preparations have therefore a ma-
jor potential role in the management of mus-
culoskeletal disorders. However, it is of utmost 
importance that the efficacy and safety of these 
remedies are sustained by well-designed clin-
ical studies, conducted with standardized and 
reproducible preparations meeting high-quality 
requirements.
BSEs have long been used for the treatment 
of musculoskeletal disorders, given their marked 
anti-inflammatory activity and their ability to 
promote tissue regeneration. However, standard 
preparations of BAs show overall modest phar-
macokinetic properties, a limitation which may 
ultimately lead to reduced efficacy.
In an effort to improve the pharmacokinetic 
properties of BAs, Casperome® a lecithin-based 
formulation of BSa representing the whole nat-
ural bouquet of Boswellia, has been developed. 
This formulation was effective in a number of 
clinical studies on different conditions based on 
inflammation, such as asthma, ulcerative colitis 
and inflammatory bowel syndrome11,14,16. More-
over, Casperome® was effective in the treatment 
of Achilles tendonitis, epicondylitis, radiculopa-
thies, ankle sprains and sport injuries alone or in 
combinations as shown by several trials, the ma-
Figure 1. Pain-free walking distance, at baseline and 
after a 4-week follow-up, in elite young rugby players who 
received Casperome®+standard management (n=25) or 
standard management only (n=27) for the treatment of a 
sport-related injury. p<0.05 for Casperome®+standard ma-
nagement vs. standard management only at week 4.
Figure 2. Need of analgesic therapy, after a 4-week fol-
low-up, in elite young rugby players who received Caspe-
rome®+standard management (n=25) or standard manage-
ment only (n=27) for the treatment of a sport-related injury. 
p<0.05 for Casperome®+standard management vs. standard 
management only.
A. Riva, P. Allegrini, F. Franceschi, S. Togni, L. Giacomelli, R. Eggenhoffner
5262
jority of which with a randomized design and all 
evaluating a number of well-recognized parame-
ters of efficacy for the therapy of musculoskeletal 
disorder2,30-33. All clinical studies were consistent 
in showing a prompt decrease of pain and im-
provement of functionality of the affected area 
after Casperome® supplementation, without any 
relevant adverse effect. Remarkably, these symp-
tomatic improvements were paralleled by reduced 
plasmatic levels of inflammatory markers and by 
a diminished need for rescue analgesics.
Conclusions
On these bases, Casperome®, under proper 
medical control and within an integrated manage-
ment, does have a role in the treatment of mus-
culoskeletal disorders. Studies in other similar 
conditions (e.g., osteoarthritis) appear warranted 
to further investigate and extend the efficacy of 
this phytosome to more specific settings.
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